Kanji Sugita

Kanji Sugita

Auto-generated profile, based on publicly available information

Kanji Sugita

Department of Pediatrics, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
FSFumikazu Sano
Fumikazu Sano
ESEiji Shigetomi
Eiji Shigetomi
YSYouichi Shinozaki
Youichi Shinozaki
HTHaruka Tsuzukiyama
Haruka Tsuzukiyama
KSKozo Saito
Kozo Saito
Schuichi KoizumiSchuichi Koizumi
Schuichi Koizumi
Extensive activation of glial cells during a latent period has been well documented in various animal models of epilepsy. However, it remains unclear whether activated glial cells contribute to epileptogenesis, i.e., the chronically persistent process leading to epilepsy. Particularly, it is not clear whether interglial communication between different types of glial cells contributes to epileptogenesis, because past literature has mainly focused on one type of glial cell. Here, we show that temporally distinct activation profiles of microglia and astrocytes collaboratively contributed to epileptogenesis in a drug-induced status epilepticus model. We found that reactive microglia appeared first, followed by reactive astrocytes and increased susceptibility to seizures. Reactive astrocytes exhibited larger Ca 2+ signals mediated by IP 3 R2, whereas deletion of this type of Ca 2+ signaling reduced seizure susceptibility after status epilepticus. Immediate, but not late, pharmacological inhibition of microglial activation prevented subsequent reactive astrocytes, aberrant astrocyte Ca 2+ signaling, and the enhanced seizure susceptibility. These findings indicate that the sequential activation of glial cells constituted a cause of epileptogenesis after status epilepticus. Thus, our findings suggest that the therapeutic target to prevent epilepsy after status epilepticus should be shifted from microglia (early phase) to astrocytes (late phase).

1 September 2015 in Epilepsy Research
Verified
Journal Article
Closed access
HKHideaki Kanemura
Hideaki Kanemura
FSFumikazu Sano
Fumikazu Sano
TOTetsuo Ohyama
Tetsuo Ohyama
SMSonoko Mizorogi
Sonoko Mizorogi
KSKanji Sugita
Kanji Sugita
MAMasao Aihara
Masao Aihara

15 October 2007 in Cancer Research
Verified
Journal Article
Open access
PDF file
YFYoshiyuki Furuichi
Yoshiyuki Furuichi
KGKumiko Goi
Kumiko Goi
TITakeshi Inukai
Takeshi Inukai
HSHiroki Sato
Hiroki Sato
ANAtsushi Nemoto
Atsushi Nemoto
KSKanji Sugita
Kanji Sugita
Fms-like tyrosine kinase 3 (FLT3) is highly expressed in acute lymphoblastic leukemia with the mixed-lineage leukemia (MLL) gene rearrangement refractory to chemotherapy. We examined the biological effect of FLT3-ligand (FL) on 18 B-precursor leukemic cell lines with variable karyotypic abnormalities, and found that nine of nine MLL-rearranged cell lines with wild-type FLT3, in contrast to other leukemic cell lines, are significantly inhibited in their proliferation in a dose-dependent manner by FL. This inhibition was due to induction of the G0-G1 arrest. A marked up-regulation of p27 by suppression of its protein degradation and an abrogation of constitutive signal transducers and activators of transcription 5 phosphorylation were revealed in arrested leukemia cells after FL stimulation. Importantly, FL treatment rendered not only cell lines but also primary leukemia cells with MLL rearrangement resistant to chemotherapeutic agents. MLL-rearranged leukemia cells adhering to the bone marrow stromal cell line, which expresses FL as the membrane-bound form, were induced to quiescent state resistant to chemotherapeutic agents, but their chemosensitivity was significantly restored in the presence of neutralizing anti-FL antibody. The FL/FLT3 interaction between leukemia cells and bone marrow stromal cells expressing FL at high levels should contribute, at least in part, to persistent minimal-residual disease of MLL-rearranged leukemia in bone marrow. [Cancer Res 2007;67(20):9852–61]

1 June 2017 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SKShin Kasai
Shin Kasai
YFYoshiyuki Furuichi
Yoshiyuki Furuichi
NANorie Ando
Norie Ando
KKKeiko Kagami
Keiko Kagami
MAMasako Abe
Masako Abe
KSKanji Sugita
Kanji Sugita
Acute lymphoblastic leukemia (ALL) with mixed lineage leukemia (MLL) gene rearrangements (MLL+ALL) has a dismal prognosis and is characterized by high surface CD44 expression. Known that CD44 has the specific binding sites for a natural ligand hyaluronan (HA), we investigated biological effects of HA with different molecular sizes on MLL+ALL cell lines, and found that the addition of ultra-low-molecular-weight (ULMW)-HA strongly suppressed their thymidine uptakes. The MLL+ALL cell line lacking surface CD44 expression established by genome editing showed no suppression of thymidine uptake. Surface CD44-high B-precursor ALL cell lines other than MLL+, but not T-ALL cell lines, were also suppressed in their thymidine uptakes. The inhibition of thymidine uptakes was because of induction of cell death, but dead cells lacked features of apoptosis on cytospin smears and flow cytometric analysis. The cell death was neither blocked by pan-caspase inhibitor nor autophagy inhibitor, but was completely blocked by necrosis inhibitor necrostatin-1. Necrotic cell death was further supported by a marked release of a high-mobility protein group B1 and morphological changes on transmission electron microscopy. Elevation of intracellular reactive oxygen species production suggested a role for inducing this necrotic cell death. ULMW-HA-triggered cell death was similarly demonstrated in surface CD44-high primary B-precursor leukemia cells. Assuming that ULMW-HA is abundantly secreted at the site of infection and inflammation, this study sheds light on understanding the mechanism of a transient inflammation-associated remission of leukemia. Further, the CD44-targeting may become an effective approach in future for the treatment of refractory B-precursor ALL by its capability of predominantly eradicating CD44-high leukemia-initiating cells.

23 September 2015 in Epilepsy & Behavior
Verified
Journal Article
Closed access
PDF file
HKHideaki Kanemura
Hideaki Kanemura
FSFumikazu Sano
Fumikazu Sano
TOTetsuo Ohyama
Tetsuo Ohyama
KSKanji Sugita
Kanji Sugita
MAMasao Aihara
Masao Aihara

31 July 2011 in Leukemia Research
Verified
Journal Article
Closed access
PDF file
XZXiaochun Zhang
Xiaochun Zhang
TITakeshi Inukai
Takeshi Inukai
KAKoshi Akahane
Koshi Akahane
KHKinuko Hirose
Kinuko Hirose
IKItaru Kuroda
Itaru Kuroda
KSKanji Sugita
Kanji Sugita